Joseph Driscoll - Mar 23, 2022 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role: Chief Financial Officer
Signature: /s/ Joseph Driscoll, by Brian McKelligon, as Attorney-in-Fact
Stock symbol: AKYA
Transactions as of: Mar 23, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/25/2022, 07:23 PM
Next filing: Dec 16, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKYA	Common Stock	Award		+12.5K			12.5K	Mar 23, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKYA	Employee Stock Option (Right to Buy)	Award	$0	+25K		$0.00	25K	Mar 23, 2022	Common Stock	25K	$11.88	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock units shall vest in four (4) equal annual installments beginning on the first anniversary of the grant date and on each anniversary thereafter.
F2	Each restricted stock unit represents a contingent right to receive one share of Akoya Biosciences, Inc. common stock.
F3	The options shall vest as follows: twenty-five percent (25%) shall vest on the first anniversary of the grant date with the remainder vesting in 36 equal monthly installments beginning on April 23, 2023.